KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Tax Provisions (2019 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Tax Provisions for 11 consecutive years, with $15.7 million as the latest value for Q1 2026.

  • For Q1 2026, Tax Provisions fell 1.39% year-over-year to $15.7 million; the TTM value through Mar 2026 reached $9.2 million, up 110.72%, while the annual FY2025 figure was $9.4 million, 109.48% up from the prior year.
  • Tax Provisions hit $15.7 million in Q1 2026 for Alnylam Pharmaceuticals, up from -$25.3 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $30.9 million in Q2 2025 and bottomed at -$110.2 million in Q4 2024.
  • Average Tax Provisions over 5 years is -$3.7 million, with a median of $1.8 million recorded in 2023.
  • Year-over-year, Tax Provisions skyrocketed 13091.3% in 2023 and then tumbled 60315.85% in 2024.
  • Alnylam Pharmaceuticals' Tax Provisions stood at $472000.0 in 2022, then crashed by 61.23% to $183000.0 in 2023, then crashed by 60315.85% to -$110.2 million in 2024, then soared by 77.06% to -$25.3 million in 2025, then surged by 161.95% to $15.7 million in 2026.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $15.7 million, -$25.3 million, and -$12.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.